Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD
Rabinovich Roberto A., Miller Bruce E., Wrobel Karolina, Ranjit Kareshma, Williams Michelle C., Drost Ellen, Edwards Lisa D., Lomas David A., Rennard Stephen I., Agustí Alvar, Tal-Singer Ruth, Vestbo Jørgen, Wouters Emiel F.M., John Michelle, van Beek Edwin J.R., Murchison John T, Bolton Charlotte E, MacNee William, Huang Jeffrey T.J.
Source: Eur Respir J 2016; 47:1365-1373
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Rabinovich Roberto A., Miller Bruce E., Wrobel Karolina, Ranjit Kareshma, Williams Michelle C., Drost Ellen, Edwards Lisa D., Lomas David A., Rennard Stephen I., Agustí Alvar, Tal-Singer Ruth, Vestbo Jørgen, Wouters Emiel F.M., John Michelle, van Beek Edwin J.R., Murchison John T, Bolton Charlotte E, MacNee William, Huang Jeffrey T.J.. Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. Eur Respir J 2016; 47:1365-1373
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019 Year: 2019
Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018
Elevated pulmonary vascular resistance predicts mortality in COPD patients Source: Eur Respir J, 58 (2) 2100944; 10.1183/13993003.00944-2021 Year: 2021
Frequency of occurrence of risk factors of cardiovascular diseases and assessment of the total cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Elevated circulating MMP-9 is associated with increased exacerbation risk in COPD: results from SPIROMICS and COPDGene Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
COPD is associated with an increased risk of peripheral artery disease and mortality Source: ERJ Open Res, 4 (4) 00086-2018; 10.1183/23120541.00086-2018 Year: 2018
Desmosine is a predictor of long-term cardiovascular mortality in bronchiectasis Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020
Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011
Neutrophils and the increased risk of cardiovascular events in severe COPD Source: Annual Congress 2012 - Distinguishing phenotypes and dealing with comorbidities in primary care Year: 2012
Does serum uric acid levels predict in-hospital mortality in severe COPD exacerbations? Source: International Congress 2015 – COPD: interesting notes Year: 2015
Elevated pulmonary vascular resistance is associated with increased risk of death in IPF Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019
Glitazones are associated with reduced risk of COPD exacerbations and mortality among patients with diabetes Source: Annual Congress 2011 - COPD: burden of disease, imaging and management Year: 2011
Acute exacerbation in COPD and relationship between cardiovascular risk and functional profile Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings Year: 2018
Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients Source: Eur Respir J, 57 (3) 2000918; 10.1183/13993003.00918-2020 Year: 2021
Correlates and assessment of excess cardiovascular risk in bronchiectasis Source: Eur Respir J, 50 (5) 1701127; 10.1183/13993003.01127-2017 Year: 2017
In people at high risk of cardiovascular disease, co-existing COPD is not independently associated with macrovascular or microvascular disease Source: International Congress 2018 – New determinants of cardiovascular morbidity in COPD Year: 2018
Interstitial lung diseases, mortality and associated risk factors Source: Eur Respir J 2004; 24: Suppl. 48, 667s Year: 2004
Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021
The impact of airway infection on cardiovascular risk during COPD exacerbations Source: Annual Congress 2012 - Acute exacerbation in COPD Year: 2012
hsCRP is associated with 10-year mortality in COPD. Source: Virtual Congress 2020 – Mechanism or pathways of chronic lung diseases Year: 2020